Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome

COVID-19 is an infectious disease caused by the beta coronavirus SARS-CoV-2, which became widespread worldwide in 2020. In most severe patients, the clinical picture begins with respiratory failure, then progressing to polyorgan failure. The most adverse prognostic sign is the development of coagulopathy. Based on the analysis of clinical data available to date, 71.4% of those who died and 0.6% of those who survived showed signs of explicit disseminated intravascular coagulation syndrome (DIC-syndrome). Monitoring of D-dimer, prothrombin time (PT), platelet and fibrinogen count are important for determining treatment and indications for hospitalization among patients with COVID-19. If these parameters deteriorate, more "aggressive" intensive care should be performed. Lowmolecular weight heparin (LMWH) should be administered to all patients with diagnosed COVID-19 infection (including non-critical patients) who require hospitalization if these patients have no contraindications for LMWH.